Insulin resistance is increasingly recognized as a significant factor linked to the development and progression of Alzheimer’s disease (AD), though it is not considered the sole cause. Research shows that impaired insulin signaling in the brain contributes to neurodegenerative processes characteristic of AD, suggesting a strong association between insulin resistance and Alzheimer’s pathology[1][3].
Insulin resistance occurs when cells in the body, including brain cells, become less responsive to insulin, a hormone crucial for regulating glucose metabolism. This condition is commonly seen in Type 2 diabetes (T2D), which epidemiological studies have repeatedly linked to a higher risk of developing AD. For example, the Rotterdam Study found that individuals with T2D have about twice the risk of developing Alzheimer’s compared to non-diabetics[1]. Other studies report a 65% increased risk of AD in diabetic populations[1]. These findings indicate that systemic metabolic dysfunction, particularly involving insulin resistance, plays a critical role in cognitive decline and dementia.
At the molecular level, insulin signaling in the brain affects neuronal survival, synaptic plasticity, and memory formation. Disruption of insulin pathways can lead to impaired glucose metabolism in neurons, oxidative stress, and inflammation, all of which contribute to the hallmark features of AD such as amyloid-beta plaque accumulation and tau protein tangles[1][3]. Experimental animal models reinforce this link: mice genetically modified to lack insulin or insulin-like growth factor 1 (IGF-1) receptors show both glucose intolerance and cognitive deficits similar to those seen in AD[1]. Moreover, crossing AD mouse models with diabetic strains accelerates cognitive decline and worsens insulin signaling in the brain[1].
Genome-wide association studies (GWAS) have identified genetic variants related to insulin resistance and glucose metabolism as contributors to AD risk, further supporting a biological connection between metabolic dysfunction and neurodegeneration[1][6]. These genetic insights highlight that insulin resistance is not merely a peripheral metabolic issue but also a central factor influencing brain aging and disease susceptibility.
Clinically, biomarkers of insulin resistance correlate with dementia risk. The Estimated Glucose Disposal Rate (eGDR), a measure of insulin sensitivity, has been shown to predict the risk of Alzheimer’s and other dementias in large diabetic cohorts. Higher eGDR values, indicating better insulin sensitivity, are associated with significantly reduced risks of AD and vascular dementia[2]. This suggests that maintaining insulin sensitivity could be a viable strategy to lower dementia risk.
The relationship between insulin resistance and AD appears to be bidirectional. While insulin resistance can exacerbate AD pathology, the neurodegenerative changes in AD may also impair insulin signaling in the brain, creating a vicious cycle that accelerates cognitive decline[1]. This interplay complicates the understanding of causality but underscores the importance of metabolic health in brain aging.
Lipid metabolism also intersects with insulin resistance in influencing AD risk. Altered lipid handling, particularly involving apolipoprotein E (ApoE), a major genetic risk factor for AD, interacts with insulin signaling pathways to affect neuronal health and amyloid processing[1]. This multifaceted metabolic dysfunction suggests that both glucose and lipid metabolism abnormalities contribute to AD pathogenesis.
Given the strong association between insulin resistance and Alzheimer’s disease, therapeutic strategies targeting metabolic dysfunction are under investigation. Repurposing diabetes medications, such as insulin sensitizers, is a promising approach to modify disease progression in AD patients[1]. Nutritional interventions that improve insulin sensitivity, like carbohydrate restriction, may also support brain health and delay cognitive decline[1].
In summary, while insulin resistance alone does not cause Alzheimer’s disease, it is a major contributing factor that exacerbates neurodegenerative processes. The evidence from epidemiological studies, animal models, genetic research, and clinical biomarkers collectively supports the view that impaired insulin signaling in the brain plays a critical role in the development and progression of AD.
—
Sources:
[1] Frontiers in Neuroscience, 2025: “Systemic lipi
